Literature DB >> 9056686

Effects of erythropoietin on endothelin-1 synthesis and the cellular calcium messenger system in vascular endothelial cells.

V Vogel1, H J Kramer, A Bäcker, H Meyer-Lehnert, W Jelkmann, J Fandrey.   

Abstract

A rise in blood pressure is the main side effect of erythropoietin (EPO) treatment in patients with renal anemia. The mechanisms, however, by which EPO may cause hypertension are still unclear. We therefore investigated the effects of EPO on endothelin (ET) synthesis and cytosolic free calcium concentration ([Ca2+]i) in vascular endothelial cells. Porcine endothelial cells were isolated from thoracic aorta, pulmonary artery, and vena cava. Studies were performed with cells of the first subculture. ET concentrations were measured radioimmunologically. Changes in [Ca2+]i were determined with the fluorescent probe fura-2. Cytotoxicity was assessed by sodium 3'-[1-(phenyl-amino-carbonyl)-3,4-tetrazolium]-bis(4-methoxy-6-nitro)ben zene sulfonic acid hydrate (XTT) assay. ET synthesis was similar in cells of different vascular origins and was time-dependent, reaching approximately 2 pmol ET/mg protein within 12 h of incubation. EPO (12 to 200 U/mL) stimulated ET release time- and dose-dependently by up to 83.2% (P < .01) within 12 h in the absence of fetal calf serum and heparin. EPO induced an immediate significant rise in [Ca2+]i from 58 +/- 12 nmol/L to 495 +/- 85 nmol/L (P < .01) with a subsequent slow return to 257 +/- 3 nmol/L. During 2 h of incubation, the Ca-ionophore A 23187 (10(-8) mol/L) moderately but significantly stimulated endothelial ET synthesis. However, the Ca-channel blocker verapamil, the intracellular Ca-release blocker TMB-8, and nickel, an unspecific calcium channel blocker, had no consistent effects on [Ca2+]i or ET synthesis. The protein kinase C inhibitor H-7 stimulated basal [Ca2+]i and cellular ET synthesis. The tyrosine kinase inhibitor genistein suppressed the EPO-induced rise in [Ca2+]i and cellular ET synthesis. From these data we conclude that EPO may stimulate ET synthesis in vascular endothelial cells by activation of an EPO-receptor and via intracellular signalling mechanisms that comprise tyrosine kinase activation and a rise in [Ca2+]i. Therefore, the systemic hypertensive effects of EPO may be due at least in part to local stimulation of vascular endothelial ET synthesis via calcium mobilization.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9056686     DOI: 10.1016/s0895-7061(96)00410-4

Source DB:  PubMed          Journal:  Am J Hypertens        ISSN: 0895-7061            Impact factor:   2.689


  8 in total

1.  AMPK is involved in mediation of erythropoietin influence on metabolic activity and reactive oxygen species production in white adipocytes.

Authors:  Li Wang; Lijun Di; Constance Tom Noguchi
Journal:  Int J Biochem Cell Biol       Date:  2014-06-19       Impact factor: 5.085

2.  Effect of 1-week treatment with erythropoietin on the vascular endothelial function in anaesthetized rabbits.

Authors:  K Noguchi; S Yamashiro; T Matsuzaki; M Sakanashi; J Nakasone; K Miyagi; M Sakanashi
Journal:  Br J Pharmacol       Date:  2001-06       Impact factor: 8.739

3.  Recombinant human erythropoietin suppresses endothelial cell apoptosis and reduces the ratio of Bax to Bcl-2 proteins in the aortas of apolipoprotein E-deficient mice.

Authors:  Jeffrey S Warren; Ying Zhao; Raymond Yung; Anjali Desai
Journal:  J Cardiovasc Pharmacol       Date:  2011-04       Impact factor: 3.105

4.  Systemic injection of recombinant human erythropoietin after focal cerebral ischemia enhances oligodendroglial and endothelial progenitor cells in rat brain.

Authors:  Young Jae Kim; Yong-Wook Jung
Journal:  Anat Cell Biol       Date:  2010-06-30

5.  Far-western blotting as a solution to the non-specificity of the anti-erythropoietin receptor antibody.

Authors:  Barbora Fecková; Patrícia Kimáková; Lenka Ilkovičová; Erika Szentpéteriová; Nataša Debeljak; Zuzana Solárová; Veronika Sačková; Martina Šemeláková; Mangesh Bhide; Peter Solár
Journal:  Oncol Lett       Date:  2016-06-24       Impact factor: 2.967

6.  Recombinant herpes simplex virus type 1 engineered for targeted binding to erythropoietin receptor-bearing cells.

Authors:  S Laquerre; D B Anderson; D B Stolz; J C Glorioso
Journal:  J Virol       Date:  1998-12       Impact factor: 5.103

7.  Role of erythropoietin in the angiogenic activity of bone marrow endothelial cells of MGUS and multiple myeloma patients.

Authors:  Aurelia Lamanuzzi; Ilaria Saltarella; Arianna Ferrucci; Roberto Ria; Simona Ruggieri; Vito Racanelli; Luigia Rao; Tiziana Annese; Beatrice Nico; Angelo Vacca; Domenico Ribatti
Journal:  Oncotarget       Date:  2016-03-22

8.  Activation of the β-common receptor by erythropoietin impairs acetylcholine-mediated vasodilation in mouse mesenteric arterioles.

Authors:  Cody R Kilar; YanPeng Diao; Larysa Sautina; Sivakumar Sekharan; Shahar Keinan; Bianca Carpino; Kirk P Conrad; Rajesh Mohandas; Mark S Segal
Journal:  Physiol Rep       Date:  2018-06
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.